Shareholders Approve 20-40 for 1 Reverse Stock Split and CEO Compensation Plan
VREOF sits 27% above its 52-week low of $0.323.
Summary
Vireo Growth Inc. shareholders approved a reverse stock split (20-40 for 1) to enhance marketability and ratified an amended employment agreement for CEO John Mazarakis, including a securities distribution.
Key Events · Corporate Governance and Compliance · VREOF
-
Shareholder Meeting Results
All six proposals submitted to shareholders at the annual general and special meeting on May 29, 2026, were approved.
-
Reverse Stock Split Approved
Shareholders approved a reverse stock split (consolidation) at a ratio between 20-for-1 and 40-for-1, at the Board's discretion. This follows previous proxy filings seeking this approval.
-
CEO Compensation Plan Approved
An amendment to CEO John Mazarakis's employment agreement and a related distribution of securities were approved by shareholders.
-
Director Elections
Seven director nominees, including Dr. Kyle E. Kingsley and John Mazarakis, were elected to the Board.
Analysis · VREOF · Life Sciences
Shareholders of Vireo Growth Inc. have approved a significant reverse stock split, allowing the Board to consolidate shares at a ratio between 20-for-1 and 40-for-1. This move is critical for improving the company's stock marketability and potentially meeting exchange listing requirements, especially given its current low share price. Additionally, shareholders approved an amended employment agreement for CEO John Mazarakis, including a distribution of securities, which is a key executive compensation event.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VREOF was trading at $0.41 on OTC in the Life Sciences sector, with a market capitalization of approximately $480.5M. The 52-week trading range was $0.32 to $0.80. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.